Preliminary list of Heteroptera (Hemiptera) species from Santa Catalina Reserve (Lomas de Zamora, Buenos Aires)

Se presenta una lista preliminar de 117 especies de Heteroptera (Hemiptera) encontradas en la Reserva Natural Santa Catalina, partido de Lomas de Zamora, Provincia de Buenos Aires. Se comenta la relevancia de algunas de ellas tanto por su importancia taxonómica como por su rol en la naturaleza, y se mencionan las plantas huésped. Se citan por primera vez para la provincia de Buenos Aires a seis especies: Repipta ayelenae Martin-Park et al., 2012 (Reduviidae), Carvalhotingis hollandi (Drake, 1935) (Tingidae) y Cyrtotylus wygodzinskyi Carvalho, 1950, Hyalochloria brasiliana Henry, 1978, Dagbertus phaleratus (Berg, 1892) y Derophthalma reuteriana Carvalho y Gomes, 1980 (Miridae).A preliminary list of 117 species of Heteroptera (Hemiptera) found in Santa Catalina Natural Reserve, Lomas de Zamora District, Buenos Aires Province, is presented. The relevance of some of them is commented both for their taxonomic importance and for their role in nature, as well as their host plants are given. Six species are cited for Buenos Aires province for the first time: Repipta ayelenae Martin-Park et al., 2012 (Reduviidae), Carvalhotingis hollandi (Drake, 1935) (Tingidae) and Cyrtotylus wygodzinskyi Carvalho, 1950, Hyalochloria brasiliana Henry, 1978, Dagbertus phaleratus (Berg, 1892) and Derophthalma reuteriana Carvalho and Gomes, 1980 (Miridae).Fil: Carpintero, Diego Leonardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Museo Argentino de Ciencias Naturales "Bernardino Rivadavia"; ArgentinaFil: de Magistris, Alberto Antonio. Universidad Nacional de Lomas de Zamora; ArgentinaFil: Petti, Carolina. No especifíca

On the presence of Coridromius chenopoderis Tatarnic y Cassis, 2008 (HEMIPTERA: HETEROPTERA: MIRIDAE) in Argentina

Se cita por primera vez para la Argentina a la especie Coridromius chenopoderis (Tatarnic y Cassis) (Heteroptera: Miridae: Orthotylinae: Coridromiini). Se muestran imágenes de ejemplares colectados y se dan sus caracteres diagnósticos. Se comenta brevemente la importancia de la aparición de esta especie en el país.The species Coridromius chenopoderis (Tatarnic and Cassis) (Heteroptera: Miridae: Orthotylinae: Coridromiini) is recorded for the first time for Argentina. Images of collected specimens are shown and their diagnostic characters are given. The importance of the appearance of this species in the country is briefly commented.Fil: Carpintero, Diego Leonardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Museo Argentino de Ciencias Naturales "Bernardino Rivadavia"; Argentina. Fundación de Historia Natural Félix de Azara; Argentina. Universidad Maimónides. Centro de Ciencias Naturales, Ambientales y Antropológicas; ArgentinaFil: Holgado, Miriam M.. Universidad Nacional de Cuyo. Facultad de Ciencias Agrarias; ArgentinaFil: de Magistris, Alberto Antonio. Universidad Nacional de Lomas de Zamora. Facultad de Ciencias Agrarias; Argentin

Ultrastructural changes in enterocytes in subjects with Hashimoto's thyroiditis

We have recently described1 mucosal ultrastructural impairments, such as height and thickness of microvilli, space between microvilli, and thickness of tight junctions, in non-coeliac type 1 diabetic patients after a preliminary report of an alteration in intestinal mucosal permeability (IP) evaluated by the lactulose/mannitol (LA/MA) test.2,3 Therefore, in the “aetiological” classification of autoimmunity based on initiating factors,4 the category of diet induced diseases could be expanded to include type 1 diabetes and, perhaps, other endocrine autoimmune diseases. Thyroiditis is the most frequently associated autoimmune endocrine disease with type 1 diabetes. Moreover, type 1 diabetes and Hashimoto thyroiditis present similar pathogenetic mechanisms of cellular damage, a cell mediated autoimmunity induced by Th1 cytokines. However, mucosal intestinal morphology and function have not yet been studied in autoimmune thyroiditis patients. Hence we investigated intestinal mucosal ultrastructural morphology and IP in a group of patients with autoimmune thyroiditis. The study was approved by the local ethics committee. Fourteen patients (12 females and 2 males; mean age 33.2 (SD 10.2) years) and 23 controls (12 females and 11 males; mean age 27.9 (SD 8.01) years) were enrolled into the study after giving written informed consent. The diagnosis of autoimmune thyroiditis was based on the following criteria: plasma autoantibody TPO positive at high titre and a typical thyroiditis ultrasound pattern. All patients were in euthyroidism (normal FT3, FT4, and TSH plasma levels without hormonal therapy). Mean duration of known disease was 5.2 (2.5) years. All patients were negative for the presence of antigliadin antibodies IgA and IgG, antiendomysium antibodies IgA, as well as antihuman transglutaminase IgA following a gluten rich Mediterranean diet. Type 1 diabetes mellitus was excluded according to the 1997 American Diabetes Association criteria, and none of the participants had a family history of diabetes mellitus. Other intestinal and endocrine diseases were excluded through clinical and, when indicated, laboratory evaluation. Food or other allergies were excluded. None of the subjects reported gastrointestinal signs or symptoms, or was a habitual smoker, abuser of alcohol, or regularly took non-steroidal anti-inflammatory drugs

The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update

Gluten-related disorders have recently been reclassified with an emerging scientific literature supporting the concept of non-celiac gluten sensitivity (NCGS). New research has specifically addressed prevalence, immune mechanisms, the recognition of non-immunoglobulin E (non-IgE) wheat allergy and overlap of NCGS with irritable bowel syndrome (IBS)-type symptoms. This review article will provide clinicians with an update that directly impacts on the management of a subgroup of their IBS patients whose symptoms are triggered by wheat ingestion

Earthquake Geotechnical Engineering Aspects of the 2012 Emilia-Romagna Earthquake (Italy)

On May 20, 2012 an earthquake of magnitude ML=5.9 struck the Emilia Romagna Region of Italy and a little portion of Lombardia Region. Successive earthquakes occurred on May 29, 2012 with ML=5.8 and ML=5.3. The earthquakes caused 27 deaths, of which 13 on industrial buildings. The damage was considerable. 12,000 buildings were severely damaged; big damages occurred also to monuments and cultural heritage of Italy, causing the collapse of 147 campaniles. The damage is estimated in about 5-6 billions of euro. To the damage caused to people and buildings, must be summed the indirect damage due to loss of industrial production and to the impossibility to operate for several months. The indirect damage could be bigger than the direct damage caused by the earthquake. The resilience of the damaged cities to the damage to the industrial buildings and the lifelines was good enough, because some industries built a smart campus to start again to operate in less of one month and structural and geotechnical guidelines were edited to start with the recovering the damage industrial buildings. In the paper a damage survey is presented and linked with the ground effects. Among these, soil amplification and liquefaction phenomena are analyzed, basing on the soil properties evaluation by field and laboratory tests. Particular emphasis is devoted to the damaged suffered by the industrial buildings and to the aspects of the remedial work linked with the shallow foundation inadequacy and to the liquefaction mitigation effects

Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Experts' Criteria

Non-Celiac Gluten Sensitivity (NCGS) is a syndrome characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing food, in subjects that are not affected by either celiac disease or wheat allergy. Given the lack of a NCGS biomarker, there is the need for standardizing the procedure leading to the diagnosis confirmation. In this paper we report experts’ recommendations on how the diagnostic protocol should be performed for the confirmation of NCGS. A full diagnostic procedure should assess the clinical response to the gluten-free diet (GFD) and measure the effect of a gluten challenge after a period of treatment with the GFD. The clinical evaluation is performed using a self-administered instrument incorporating a modified version of the Gastrointestinal Symptom Rating Scale. The patient identifies one to three main symptoms that are quantitatively assessed using a Numerical Rating Scale with a score ranging from 1 to 10. The double-blind placebo-controlled gluten challenge (8 g/day) includes a one-week challenge followed by a one-week washout of strict GFD and by the crossover to the second one-week challenge. The vehicle should contain cooked, homogeneously distributed gluten. At least a variation of 30% of one to three main symptoms between the gluten and the placebo challenge should be detected to discriminate a positive from a negative result. The guidelines provided in this paper will help the clinician to reach a firm and positive diagnosis of NCGS and facilitate the comparisons of different studies, if adopted internationally

Diagnosis of Non-Celiac Gluten Sensitivity (NCGS)

Non-Celiac Gluten Sensitivity (NCGS) is a syndrome characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing food, in subjects that are not affected by either celiac disease or wheat allergy. Given the lack of a NCGS biomarker, there is the need for standardizing the procedure leading to the diagnosis confirmation. In this paper we report experts’ recommendations on how the diagnostic protocol should be performed for the confirmation of NCGS. A full diagnostic procedure should assess the clinical response to the gluten-free diet (GFD) and measure the effect of a gluten challenge after a period of treatment with the GFD. The clinical evaluation is performed using a self-administered instrument incorporating a modified version of the Gastrointestinal Symptom Rating Scale. The patient identifies one to three main symptoms that are quantitatively assessed using a Numerical Rating Scale with a score ranging from 1 to 10. The double-blind placebo-controlled gluten challenge (8 g/day) includes a one-week challenge followed by a one-week washout of strict GFD and by the crossover to the second one-week challenge. The vehicle should contain cooked, homogeneously distributed gluten. At least a variation of 30% of one to three main symptoms between the gluten and the placebo challenge should be detected to discriminate a positive from a negative result. The guidelines provided in this paper will help the clinician to reach a firm and positive diagnosis of NCGS and facilitate the comparisons of different studies, if adopted internationally

Polyphenol Intake and Epithelial Ovarian Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study

We thank Bertrand Hemon for his valuable help with the EPIC database. We also thank the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, and the National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands; Public Health Directorate, Asturias, Spain; the Oxford University, the Cambridge University, and the Imperial College of London, the UK, for their contribution and ongoing support to the EPIC Study. The authors also express their gratitude to all participants in the EPIC cohorts for their invaluable contribution to the study. This research was funded by the Women's Health Dexeus Foundation (R.Z.-R.). The coordination of EPIC is financially supported by the International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS)-Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology-ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skane and Vasterbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom). We thank CERCA Program/Generalitat de Catalunya for institutional support. R.Z.-R. would like to thank the "Miguel Servet" program (CPII20/00009) from the Institute of Health Carlos III (Spain) and the European Social Fund (ESF).Despite some epidemiological evidence on the protective effects of polyphenol intake on epithelial ovarian cancer (EOC) risk from case-control studies, the evidence is scarce from prospective studies and non-existent for several polyphenol classes. Therefore, we aimed to investigate the associations between the intake of total, classes and subclasses of polyphenols and EOC risk in a large prospective study. The study was conducted in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, which included 309,129 adult women recruited mostly from the general population. Polyphenol intake was assessed through validated country-specific dietary questionnaires and the Phenol-Explorer database. During a mean follow-up of 14 years, 1469 first incident EOC cases (including 806 serous, 129 endometrioid, 102 mucinous, and 67 clear cell tumours) were identified. In multivariable-adjusted Cox regression models, the hazard ratio in the highest quartile of total polyphenol intake compared with the lowest quartile (HRQ4vsQ1) was 1.14 (95% CI 0.94–1.39; p-trend = 0.11). Similarly, the intake of most classes and subclasses of polyphenols were not related to either overall EOC risk or any EOC subtype. A borderline statistically significant positive association was observed between phenolic acid intake (HRQ4vsQ1 = 1.20, 95% CI 1.01–1.43; p-trend = 0.02) and EOC risk, especially for the serous subtype and in women with obesity, although these associations did not exceed the Bonferroni correction threshold. The current results do not support any association between polyphenol intake and EOC in our large European prospective study. Results regarding phenolic acid intake need further investigationJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, UtrechtNational Institute for Public Health and the Environment (RIVM), Bilthoven, the NetherlandsPublic Health Directorate, Asturias, SpainOxford UniversityWorld Health OrganizationNIHR Imperial Biomedical Research Centre (BRC)Danish Cancer SocietyLigue nationale contre le cancerInstitut Gustave RoussyMutuelle Generale de l'Education NationaleInstitut National de la Sante et de la Recherche Medicale (Inserm)Deutsche Krebshilfe Helmholtz Association Federal Ministry of Education & Research (BMBF)Fondazione AIRC per la ricerca sul cancroConsiglio Nazionale delle Ricerche (CNR)Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds Dutch Prevention Funds Netherlands Organization for Scientific Research (NWO) World Cancer Research Fund (WCRF), Statistics NetherlandsHealth Research Fund (FIS)-Instituto de Salud Carlos III (ISCIII)Swedish Cancer Society Swedish Research CouncilEuropean CommissionVasterbotten (Sweden)Cancer Research UK 14136 C8221/A29017UK Research & Innovation (UKRI) Medical Research Council UK (MRC)European Commission 1000143 MR/M012190/1CERCA Program/Generalitat de Catalunya CPII20/00009 Instituto de Salud Carlos IIIEuropean Social Fund (ESF)University of CambridgeImperial College of London, the UKWomen's Health Dexeus Foundatio

The SPL (II) at CERN, a Superconducting 3.5 GeV H- Linac

A revision of the physics needs and recent progress in the technology of superconducting (SC) RF cavities have triggered major changes in the design of a SC H-linac at CERN. With up to 5MW beam power, the SPL can be the proton driver for a next generation ISOL-type radioactive beam facility (âEURISOLâ) and/or supply protons to a neutrino () facility (conventional superbeam + beta-beam or -factory). Furthermore the SPL can replace Linac2 and the PS booster (PSB), improving significantly the beam performance in terms of brightness, intensity, and reliability for the benefit of all proton users at CERN, including LHC and its luminosity upgrade. Compared with the first conceptual design, the beam energy is almost doubled (3.5GeV instead of 2.2 GeV) while the length is reduced by 40%. At a repetition rate of 50 Hz, the linac reuses decommissioned 352.2MHz RF equipment from LEP in the low-energy part. Beyond 90MeV the RF frequency is doubled, and from 180MeV onwards high-gradient SC bulkniobium cavities accelerate the beam to its final energy of 3.5GeV. This paper presents the overall design approach, together with the technical progress since the first conceptual design in 2000